NASDAQ · TARA
Healthcare · Biotechnology
$3.70
Down-$0.03 (-0.76%)
Updated Sep 18, 2026, 6:44 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TARA closed at $3.70 after 20 trading sessions, down 5.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $3.65 | $3.76 | $3.62 | $3.70 | 654.16K |
| Sep 16, 2026 | $3.78 | $3.87 | $3.615 | $3.62 | 2.06M |
| Sep 15, 2026 | $3.91 | $3.94 | $3.74 | $3.75 | 901.08K |
| Sep 14, 2026 | $3.83 | $4.015 | $3.818 | $3.91 | 735.18K |
| Sep 11, 2026 | $3.83 | $3.95 | $3.81 | $3.82 | 532.03K |
| Sep 10, 2026 | $3.83 | $3.83 | $3.735 | $3.79 | 467.37K |
| Sep 9, 2026 | $3.86 | $3.945 | $3.83 | $3.83 | 287.16K |
| Sep 8, 2026 | $3.92 | $3.955 | $3.83 | $3.89 | 385.7K |
| Sep 4, 2026 | $3.93 | $3.96 | $3.89 | $3.94 | 203.01K |
| Sep 3, 2026 | $3.94 | $3.98 | $3.87 | $3.97 | 239.46K |
| Sep 2, 2026 | $3.92 | $4.0002 | $3.855 | $3.94 | 335.41K |
| Sep 1, 2026 | $3.81 | $3.915 | $3.795 | $3.90 | 222.41K |
| Aug 31, 2026 | $3.79 | $3.88 | $3.72 | $3.86 | 506.47K |
| Aug 28, 2026 | $3.99 | $3.99 | $3.785 | $3.82 | 399.08K |
| Aug 27, 2026 | $3.93 | $4.04 | $3.90 | $3.99 | 256.8K |
| Aug 26, 2026 | $3.96 | $4.05 | $3.88 | $3.91 | 763.15K |
| Aug 25, 2026 | $3.87 | $3.99 | $3.86 | $3.97 | 272.74K |
| Aug 24, 2026 | $3.84 | $3.89 | $3.715 | $3.87 | 229.88K |
| Aug 21, 2026 | $3.91 | $3.95 | $3.81 | $3.85 | 238.44K |
| Aug 20, 2026 | $3.92 | $3.93 | $3.83 | $3.90 | 360.85K |
The latest Smart Investors Daily articles mentioning TARA.
TARA research
Company profile and research snapshot.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 20, 2026 | Oppenheimer | Outperform | — |
| May 14, 2026 | JP Morgan | Overweight | — |
| Apr 29, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 4, 2026 | JP Morgan | Overweight | — |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 4, 2026
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.
SeekingAlpha · Feb 26, 2026
Yahoo · Feb 25, 2026
Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Management said
SeekingAlpha · Feb 24, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TARA.
